Strongbridge Biopharma PLC (NASDAQ: SBBP) and Mirna Therapeutics (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings for Strongbridge Biopharma PLC and Mirna Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Strongbridge Biopharma PLC 0 0 3 0 3.00
Mirna Therapeutics 0 2 1 0 2.33

Strongbridge Biopharma PLC currently has a consensus price target of $13.33, indicating a potential upside of 93.24%. Mirna Therapeutics has a consensus price target of $19.50, indicating a potential upside of 2.55%. Given Strongbridge Biopharma PLC’s stronger consensus rating and higher possible upside, research analysts clearly believe Strongbridge Biopharma PLC is more favorable than Mirna Therapeutics.

Valuation and Earnings

This table compares Strongbridge Biopharma PLC and Mirna Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Strongbridge Biopharma PLC $1.53 million 159.35 -$39.43 million ($2.78) -2.48
Mirna Therapeutics N/A N/A N/A ($9.59) -1.98

Mirna Therapeutics has higher revenue, but lower earnings than Strongbridge Biopharma PLC. Strongbridge Biopharma PLC is trading at a lower price-to-earnings ratio than Mirna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Strongbridge Biopharma PLC has a beta of 2.72, meaning that its stock price is 172% more volatile than the S&P 500. Comparatively, Mirna Therapeutics has a beta of 3.59, meaning that its stock price is 259% more volatile than the S&P 500.


This table compares Strongbridge Biopharma PLC and Mirna Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Strongbridge Biopharma PLC N/A -83.83% -34.77%
Mirna Therapeutics N/A -44.70% -42.29%

Insider & Institutional Ownership

63.7% of Strongbridge Biopharma PLC shares are owned by institutional investors. 18.6% of Mirna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Strongbridge Biopharma PLC beats Mirna Therapeutics on 7 of the 10 factors compared between the two stocks.

Strongbridge Biopharma PLC Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing’s syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Mirna Therapeutics Company Profile

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Receive News & Stock Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related stocks with our FREE daily email newsletter.